SLC5A2 and diabetes mellitus: Moreover, clinical trials in diabetes with sodium/glucose co-transporter-2 (SGLT-2) inhibitors, which increase plasma ketones (38), show markedly reduced risk of cardiovascular events and kidney failure (39).